VAPB and Parkinson disease: On the contrary, the same analysis performed with the polyclonal antibody did not reveal significant differences of VAPB fluorescent signals between patients with sALS and PD and HCs (Supplementary Figure S1), most likely due to the fact that the polyclonal antibody recognized more VAPB epitopes than the monoclonal antibody.